Mavenclad - (10 mg ; Tablet)

Generic Name	Cladribine	Innovator	EMD Serono
Dosage	10 mg ; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	MAVENCLAD is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults . Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** (*****)	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
******** ****** ********	** \ **	*** **, ****	********* **** ** ** / ********* ********* ** ***** ** ******** ******	****	** *** **, ****
*********	** \ **	*** **, ****	******* / ********* ********* ** ****** ** *********	****	*** ****** *** ****

Chronology Of Events